Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those ...

Insulin degludec, the ultra long-acting basal insulin from Novo Nordisk sold as Tresiba, offers the same level of cardiovascular (CV) safety as insulin glargine U100, but with a 40% reduction in ...

Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late ...

Tresiba® will be available in the FlexTouch® pen, which has no push-button extension, and will be offered in two concentrations enabling maximum doses of 80 units and 160 units per single ...

Novo Nordisk's long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.

Tresiba® is available in Novo Nordisk's newest insulin delivery device – FlexTouch® – as a 100 units/mL or 200 units/mL pen.

In Europe, Tresiba® and Ryzodeg® will be available in FlexTouch®, Novo Nordisk‟s latest prefilled insulin pen, which has an easy auto-injector mechanism.

The expanded indication of TRESIBA ® follows its first Health Canada approval in August 2017 for the treatment of adults with Type 1 and Type 2 diabetes mellitus.

Novo Nordisk has received positive CHMP decisions to expand the use of 2 of its products for type 2 diabetes. Tresiba can now be used with GLP-1 agonists such as Victoza and vice versa.

(RTTNews) - Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage ...